Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaJennifer R. Brown, Mazyar Shadman, Lugui Qiu et al.|New England Journal of Medicine|2022Cited by 453
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III TrialPeter Hillmen, Wojciech Jurczak, Barbara Eichhorst et al.|Journal of Clinical Oncology|2022Cited by 93
Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)Jennifer R. Brown, Mazyar Shadman, Barbara Eichhorst et al.|Blood|2023Cited by 24
CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaMeghan C. Thompson, John F. Seymour, Constantine S. Tam et al.|Blood|2025Cited by 1